Table 5.
Patients’ characteristics and risk factors for mortality at 28 days from the admission in ICU of CAPA patients.
| Variable | N | Death (%) | Survived (%) | p |
|---|---|---|---|---|
| Respiratory diseases | 7 | 4 (57.1%) | 3 (42.9%) | 0.970 |
| Active or past smoking | 13 | 9 (69.2%) | 4 (30.8%) | 0.321 |
| Hypertension | 21 | 15 (71.4%) | 6 (28.6%) | 0.083 |
| Cardiovascular disease | 13 | 8 (61.5%) | 5 (38.5%) | 0.745 |
| Diabetes mellitus | 16 | 10 (62.5%) | 6 (37.5%) | 0.634 |
| CKD | 8 | 5 (62.5%) | 3 (37.5%) | 0.766 |
| Haematological diseases | 3 | 2 (66.7%) | 1 (33.3%) | 0.747 |
| SOT | 3 | 3 (100%) | 0 | 0.125 |
| Malignancy | 7 | 5 (71.4%) | 2 (28.6%) | 0.426 |
| Other ID | 8 | 3 (37.5%) | 5 (62.5%) | 0.200 |
| Liver cirrhosis | 1 | 0 (0.0%) | 1 (100%) | 0.387 |
| Steroids | 41 | 24 (58.5%) | 17 (41.5%) | 0.741 |
| Immunomodulatory agents | 8 | 7 (87.5%) | 1 (12.5%) | 0.061 |
| Broad-spectrum ATB | 43 | 26 (60.5%) | 17 (39.5%) | 0.091 |
| Previous antifungal therapy | 10 | 6 (60%) | 4 (40%) | 0.872 |
| CT scan previous CAPA diagnosis | 20 | 10 (50%) | 10 (50%) | 0.345 |
| CT at CAPA diagnosis | 25 | 17 (68%) | 8 (32%) | 0.121 |
| Positive Aspergillus isolation on BAL | 19 | 14 (73.7%) | 5 (26.3%) | 0.065 |
| Positive GM on BAL | 35 | 21 (60%) | 14 (40%) | 0.572 |
| Positive serum GM | 9 | 3 (33.3%) | 6 (66.7%) | 0.097 |
| Voriconazole | 11 | 7 (63.6%) | 4 (36.4%) | 0.600 |
| Isavuconazole | 10 | 6 (60%) | 4 (40%) | 0.592 |
| Amphotericin B | 7 | 4 (57.1%) | 3 (42.9%) | 0.572 |
Abbreviations: CKD: chronic kidney disease; SOT: solid organ transplantation; CT: computed tomography; CAPA: COVID-19 associated pulmonary aspergillosis; GM: galattomannann; ID: immunedepression; ATB: antibiotic; and BAL: broncho-alveolar lavage.